Seres therapeutics achieves enrollment of 300 subjects with phase 3 ecospor iv open-label extension study of ser-109, a potentially first-in-class investigational microbiome therapeutic for recurrent c. difficile infection

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ecospor iv open-label study evaluating ser-109, an investigational oral microbiome therapeutic for recurrent c. difficile infection (rcdi). the target enrollment of a minimum of 300 subjects for the ser-109 safety database was reached in conjunction with a prior completed phase 3 study, ecospor lll. seres is re
MCRB Ratings Summary
MCRB Quant Ranking